Literature DB >> 22018806

Squirrel monkeys (Saimiri sciureus) infected with the agent of bovine spongiform encephalopathy develop tau pathology.

P Piccardo1, J Cervenak, O Yakovleva, L Gregori, K Pomeroy, A Cook, F S Muhammad, T Seuberlich, L Cervenakova, D M Asher.   

Abstract

Squirrel monkeys (Saimiri sciureus) were infected experimentally with the agent of classical bovine spongiform encephalopathy (BSE). Two to four years later, six of the monkeys developed alterations in interactive behaviour and cognition and other neurological signs typical of transmissible spongiform encephalopathy (TSE). At necropsy examination, the brains from all of the monkeys showed pathological changes similar to those described in variant Creutzfeldt-Jakob disease (vCJD) of man, except that the squirrel monkey brains contained no PrP-amyloid plaques typical of that disease. Constant neuropathological features included spongiform degeneration, gliosis, deposition of abnormal prion protein (PrP(TSE)) and many deposits of abnormally phosphorylated tau protein (p-Tau) in several areas of the cerebrum and cerebellum. Western blots showed large amounts of proteinase K-resistant prion protein in the central nervous system. The striking absence of PrP plaques (prominent in brains of cynomolgus macaques [Macaca fascicularis] with experimentally-induced BSE and vCJD and in human patients with vCJD) reinforces the conclusion that the host plays a major role in determining the neuropathology of TSEs. Results of this study suggest that p-Tau, found in the brains of all BSE-infected monkeys, might play a role in the pathogenesis of TSEs. Whether p-Tau contributes to development of disease or appears as a secondary change late in the course of illness remains to be determined. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22018806      PMCID: PMC3288625          DOI: 10.1016/j.jcpa.2011.09.004

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  59 in total

1.  Transmission of bovine spongiform encephalopathy and scrapie to mice.

Authors:  H Fraser; M E Bruce; A Chree; I McConnell; G A Wells
Journal:  J Gen Virol       Date:  1992-08       Impact factor: 3.891

Review 2.  Bovine spongiform encephalopathy.

Authors:  J W Wilesmith; G A Wells
Journal:  Curr Top Microbiol Immunol       Date:  1991       Impact factor: 4.291

3.  Feline spongiform encephalopathy: fibril and PrP studies.

Authors:  G R Pearson; J M Wyatt; T J Gruffydd-Jones; J Hope; A Chong; R J Higgins; A C Scott; G A Wells
Journal:  Vet Rec       Date:  1992-10-03       Impact factor: 2.695

4.  Distribution of experimentally induced scrapie lesions in the brain.

Authors:  H Fraser; A G Dickinson
Journal:  Nature       Date:  1967-12-30       Impact factor: 49.962

5.  Familial dementia with PrP-positive amyloid plaques: a variant of Gerstmann-Sträussler syndrome.

Authors:  D Nochlin; S M Sumi; T D Bird; A D Snow; C M Leventhal; K Beyreuther; C L Masters
Journal:  Neurology       Date:  1989-07       Impact factor: 9.910

6.  A68 is a component of paired helical filaments of Gerstmann-Sträussler-Scheinker disease, Indiana kindred.

Authors:  F Tagliavini; G Giaccone; F Prelli; L Verga; M Porro; J Q Trojanowski; M R Farlow; B Frangione; B Ghetti; O Bugiani
Journal:  Brain Res       Date:  1993-07-09       Impact factor: 3.252

7.  A new inherited prion disease (PrP-P105L mutation) showing spastic paraparesis.

Authors:  T Kitamoto; N Amano; Y Terao; Y Nakazato; T Isshiki; T Mizutani; J Tateishi
Journal:  Ann Neurol       Date:  1993-12       Impact factor: 10.422

8.  Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease.

Authors:  C Bancher; C Brunner; H Lassmann; H Budka; K Jellinger; G Wiche; F Seitelberger; I Grundke-Iqbal; K Iqbal; H M Wisniewski
Journal:  Brain Res       Date:  1989-01-16       Impact factor: 3.252

9.  Bovine spongiform encephalopathy: epidemiological studies.

Authors:  J W Wilesmith; G A Wells; M P Cranwell; J B Ryan
Journal:  Vet Rec       Date:  1988-12-17       Impact factor: 2.695

10.  Novel proteinaceous infectious particles cause scrapie.

Authors:  S B Prusiner
Journal:  Science       Date:  1982-04-09       Impact factor: 47.728

View more
  6 in total

1.  Complex proteinopathy with accumulations of prion protein, hyperphosphorylated tau, α-synuclein and ubiquitin in experimental bovine spongiform encephalopathy of monkeys.

Authors:  Pedro Piccardo; Juraj Cervenak; Ming Bu; Lindsay Miller; David M Asher
Journal:  J Gen Virol       Date:  2014-04-25       Impact factor: 3.891

Review 2.  Non-human primates in prion diseases.

Authors:  Emmanuel E Comoy; Jacqueline Mikol; Jean-Philippe Deslys
Journal:  Cell Tissue Res       Date:  2022-06-04       Impact factor: 5.249

3.  Phosphorylated human tau associates with mouse prion protein amyloid in scrapie-infected mice but does not increase progression of clinical disease.

Authors:  Brent Race; Katie Phillips; Allison Kraus; Bruce Chesebro
Journal:  Prion       Date:  2016-07-03       Impact factor: 3.931

4.  Lack of Transmission of Chronic Wasting Disease to Cynomolgus Macaques.

Authors:  Brent Race; Katie Williams; Christina D Orrú; Andrew G Hughson; Lori Lubke; Bruce Chesebro
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

5.  Candidate cell substrates, vaccine production, and transmissible spongiform encephalopathies.

Authors:  Pedro Piccardo; Larisa Cervenakova; Irina Vasilyeva; Oksana Yakovleva; Igor Bacik; Juraj Cervenak; Carroll McKenzie; Lubica Kurillova; Luisa Gregori; Kitty Pomeroy; David M Asher
Journal:  Emerg Infect Dis       Date:  2011-12       Impact factor: 6.883

6.  Unraveling the key to the resistance of canids to prion diseases.

Authors:  Natalia Fernández-Borges; Beatriz Parra; Enric Vidal; Hasier Eraña; Manuel A Sánchez-Martín; Jorge de Castro; Saioa R Elezgarai; Martí Pumarola; Tomás Mayoral; Joaquín Castilla
Journal:  PLoS Pathog       Date:  2017-11-13       Impact factor: 6.823

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.